The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization.
Extracorporeal photopheresis (ECP) has been successfully used to treat some inflammatory conditions. Following ECP, lymphocytes become apoptotic and untreated monocytes, exposed to post-ECP lymphocytes, reduce proinflammatory cytokine secretion. This study attempted to establish if this monocyte immunosuppression was linked to phosphatidylserine externalization (detected using Annexin V) on the apoptotic lymphocytes. Using density gradient and magnetic separation, lymphocytes were isolated from three cutaneous T-cell lymphoma and nine chronic graft versus host disease (cGvHD) patients pre-ECP and prior to re-infusion (post-ECP). The collected lymphocytes were cultured overnight and Annexin V levels determined. Peripheral blood was taken from the same patient 20 h later and the monocytes were isolated. The 'fresh' monocytes were introduced to each 20 h pre- and post-ECP lymphocyte culture, stimulated with lipopolysaccharide (LPS) and Brefeldin A and subsequently tested for intracellular tumour necrosis factor alpha, interleukin 1 alpha (IL1alpha), IL1beta, IL6 and IL8. For cGvHD patients, the relative levels of IL1alpha and IL6 were reduced in the untreated, LPS-stimulated monocytes exposed to post-ECP lymphocytes. However, the down-regulation of IL1alpha and IL6 did not correlate to levels of Annexin V-positive lymphocytes. ECP-treated lymphocytes can reduce the ability of LPS-stimulated monocytes to produce some proinflammatory cytokines; however, this effect is not dependent on phosphatidylserine externalization.
Haematology Department, Rotherham General Hospital, South Yorkshire, UK. john.bladon@rothgen.nhs.uk
John
J
Bladon
Peter C
PC
Taylor
D017304:Annexin A5 / Q000378:metabolism; D017209:Apoptosis; D016207:Cytokines / Q000378:metabolism; D015536:Down-Regulation; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D018836:Inflammation Mediators / Q000378:metabolism; D007375:Interleukin-1 / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism*; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000628:therapy; D009000:Monocytes / Q000276:immunology*; D010718:Phosphatidylserines / Q000378:metabolism*; D017893:Photopheresis
D017304:Annexin A5; D016207:Cytokines; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D010718:Phosphatidylserines